Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.